The cerebrovascular dilatation effects of olprinone, a phosphodiesterase III inhibitor, in comparison with acetazolamide—a pliot study

• Published in: Clinical neurology and neurosurgery 2004-09, Vol.106 (4), p.284-288
• Main Authors: Ueda, Takashi, Mizushige, Katsufumi, Yukiiri, Kazushi, Nishiyama, Yoshihiro, Kohno, Masakazu
• Format: Article
• Language: English
• Subjects: [formula omitted]-ECD brain SPECT; Acetazolamide; Biological and medical sciences; Blood pressure; Heart rate; Hypertension; Medical imaging; Medical sciences; Neurology; Neurosurgery; Olprinone; Regional cerebral blood flow; Smooth muscle; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Vasodilatation
• ISSN: 0303-8467; 1872-6968
• DOI: 10.1016/j.clineuro.2003.12.005

To examine the effects of olprinone, a phosphodiesterase III inhibitor, on cerebral blood flow (CBF), we compared the effects of olprinone on CBF to that of acetazolamide. Using technetium-99m-ethyl cysteinate dimer ( 99m Tc -ECD) brain SPECT, we measured regional CBF (rCBF) at 33 sites, including 16 right and left pairs of non-infarct cerebral cortexes, in seven stroke patients (66.0±3.2 years) in a resting state and 15 min after the administration of acetazolamide. Within 1 week, rCBF at each site was measured 15 min after the initiation of olprinone infusion. Resting rCBF showed a significant negative correlation with the change in rCBF (ΔCBF) during olprinone infusion ( r=−0.43, P=0.013), but no significant correlation was seen following acetazolamide administration. The difference in rCBF between the right and left cortex increased more following acetazolamide administration (14.1±10.9 ml/(min 100 g)) than during olprinone infusion (5.4±4.8 ml/(min 100 g), P=0.013). The rCBF at four regions of interest (ROI) with low-resting CBF (